Overview

* Nutex Health ( NUTX ) Q3 revenue increased 239.9% to $267.8 mln, driven by hospital division

* Net income for Q3 rose to $55.4 mln from a loss of $8.8 mln in 2024

* The healthcare management firm regained Nasdaq compliance, closing previous listing rule matter

Outlook

* Company did not provide specific future guidance in the press release

Result Drivers

* HOSPITAL DIVISION GROWTH - Revenue from hospital division increased significantly due to higher acuity claims and success in IDR process

* ARBITRATION SUCCESS - Co achieved high success rate in arbitration, winning over 85% of claims and collecting over 80% of wins

* STOCK COMPENSATION IMPACT - High stock-based compensation expenses due to obligations for under-construction hospitals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net $96.80

Income mln

Q3 EBIT $130.37

mln

Q3 Gross $154.88

Profit mln

Q3 $123.94

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Nutex Health Inc ( NUTX ) is $220.00, about 54.9% above its November 18 closing price of $99.20

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)